HC Wainwright Raises Legend Biotech (NASDAQ:LEGN) Price Target to $87.00
Legend Biotech (NASDAQ:LEGN – Free Report) had its price objective hoisted by HC Wainwright from $86.00 to $87.00 in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Legend Biotech’s Q1 2024 earnings at $0.14 EPS and FY2024 earnings at […]
More Stories
Oliver Luxxe Assets LLC Buys 4,368 Shares of Leonardo DRS, Inc. (NASDAQ:DRS)
Oliver Luxxe Assets LLC grew its stake in shares of Leonardo DRS, Inc. (NASDAQ:DRS – Free Report) by 5.1% during...
Oliver Luxxe Assets LLC Buys 4,368 Shares of Leonardo DRS, Inc. (NASDAQ:DRS)
Oliver Luxxe Assets LLC grew its stake in shares of Leonardo DRS, Inc. (NASDAQ:DRS – Free Report) by 5.1% during...
Oliver Luxxe Assets LLC Purchases 19,847 Shares of Mueller Industries, Inc. (NYSE:MLI)
Oliver Luxxe Assets LLC grew its position in shares of Mueller Industries, Inc. (NYSE:MLI – Free Report) by 33.5% in...
Oliver Luxxe Assets LLC Purchases 19,847 Shares of Mueller Industries, Inc. (NYSE:MLI)
Oliver Luxxe Assets LLC grew its position in shares of Mueller Industries, Inc. (NYSE:MLI – Free Report) by 33.5% in...
KLA Co. (NASDAQ:KLAC) Shares Purchased by Fortem Financial Group LLC
Fortem Financial Group LLC lifted its holdings in shares of KLA Co. (NASDAQ:KLAC – Free Report) by 2.1% in the...
KLA Co. (NASDAQ:KLAC) Shares Purchased by Fortem Financial Group LLC
Fortem Financial Group LLC lifted its holdings in shares of KLA Co. (NASDAQ:KLAC – Free Report) by 2.1% in the...